

W.C. Sernyl

January 8, 1964

Alain J. Sanseigne, M. D.
Parke, Davis & Company
Research Laboratories
2800 Plymouth Road
Ann Arbor, Michigan

Dear Dr. Sanseigne:

Some weeks ago you were kind enough to submit a protocol to us regarding Succinic Acid as an Antagonist to the Psychomimetic Effect of Sernyl, your Protocol 395-4.

In reviewing this protocol, a number of questions emerged. On page 3, section 4, I believe the diagnostic classification should be schizophrenia and sociopaths.

Page 4 stimulated a problem in interpretation. It is not customary for us to carry out repeated hematological and urinary determinations during the administration of new compounds. The protocol implies that the laboratory test on page 4 would be repeated during drug administration. Under our present laboratory organization, with only one laboratory technician assigned, we are unable to carry out these determinations, and these should either be deleted or some other provisions made if they are necessary.

In similar fashion, the Form II - Laboratory is one that we are not able to complete. In addition, the Rating Scale section related to EEG is incomplete. That section should be deleted and any ratings that are provided will be in the form of quantitative statements of frequency pattern change and will be carried out by Dr. Itil. Because of prior commitments of the EEG laboratory, I believe it may not be possible to have the

Alain J. Sanseigne, M. D.
January 8, 1964
Page Two

electroencephalograms done as part of the trial, but they will be done sufficiently frequent to provide us with information.

If you would be so kind as to modify the laboratory sections of this protocol, we shall be glad to sign it.

Sincerely yours,

Max Fink, M. D.
Director

MF:mlg
Enc. 1 - Protocol 395-4